Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors

Guanghai Jin, Sungjin Lee, Moonju Choi, Seohyun Son, Geon Woo Kim, Jong-Won Oh, Choongho Lee, Kyeong Lee

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In order to identify the inhibitors of hepatitis C virus (HCV) replication with a novel scaffold via a mechanistically unbiased approach, we screened our in-house library composed of ∼6000 compounds with various chemical structures by using the renilla luciferase-linked genotype 2a reporter virus, and we identified a series of compounds containing an indole moiety that were active against HCV replication. Based on this result, we further synthesized three groups of indole derivatives and evaluated their inhibitory effects on HCV replication. In the present structure-activity relationship study of these indole derivatives, we discovered that compound 12e was the most potent inhibitor of HCV replication with minimal cytotoxicity (EC50 = 1.1 μM, EC90 = 2.1 μM, and CC50 = 61.8 μM). We also confirmed that compound 12e caused a dose- and time-dependent reduction of viral RNA as well as viral protein levels in both genotype 2a J6/JFH1 RNA-transfected cells and genotype 1b Bart79I subgenomic replicon cells. Finally, a genetic mapping study of mutant viruses resistant to compound 12e revealed that NS5B RNA polymerase was the potential target. This finding was further validated by demonstration of inhibition of NS5B RNA polymerase in vitro by compound 12e (IC50 = 292 nM). Compound 12e may serve as a valuable candidate for the development of a new class of HCV NS5B RNA polymerase inhibitors in the future.

Original languageEnglish
Pages (from-to)413-425
Number of pages13
JournalEuropean Journal of Medicinal Chemistry
Volume75
DOIs
Publication statusPublished - 2014 Mar 21

Fingerprint

Viruses
Hepacivirus
Virus Replication
Derivatives
DNA-Directed RNA Polymerases
Genotype
Renilla Luciferases
Replicon
Viral RNA
Viral Proteins
Structure-Activity Relationship
Inhibitory Concentration 50
Libraries
Cytotoxicity
indole
Genetics
RNA
Scaffolds
Demonstrations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this

Jin, Guanghai ; Lee, Sungjin ; Choi, Moonju ; Son, Seohyun ; Kim, Geon Woo ; Oh, Jong-Won ; Lee, Choongho ; Lee, Kyeong. / Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors. In: European Journal of Medicinal Chemistry. 2014 ; Vol. 75. pp. 413-425.
@article{ae83ab46559343199215e55b31649828,
title = "Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors",
abstract = "In order to identify the inhibitors of hepatitis C virus (HCV) replication with a novel scaffold via a mechanistically unbiased approach, we screened our in-house library composed of ∼6000 compounds with various chemical structures by using the renilla luciferase-linked genotype 2a reporter virus, and we identified a series of compounds containing an indole moiety that were active against HCV replication. Based on this result, we further synthesized three groups of indole derivatives and evaluated their inhibitory effects on HCV replication. In the present structure-activity relationship study of these indole derivatives, we discovered that compound 12e was the most potent inhibitor of HCV replication with minimal cytotoxicity (EC50 = 1.1 μM, EC90 = 2.1 μM, and CC50 = 61.8 μM). We also confirmed that compound 12e caused a dose- and time-dependent reduction of viral RNA as well as viral protein levels in both genotype 2a J6/JFH1 RNA-transfected cells and genotype 1b Bart79I subgenomic replicon cells. Finally, a genetic mapping study of mutant viruses resistant to compound 12e revealed that NS5B RNA polymerase was the potential target. This finding was further validated by demonstration of inhibition of NS5B RNA polymerase in vitro by compound 12e (IC50 = 292 nM). Compound 12e may serve as a valuable candidate for the development of a new class of HCV NS5B RNA polymerase inhibitors in the future.",
author = "Guanghai Jin and Sungjin Lee and Moonju Choi and Seohyun Son and Kim, {Geon Woo} and Jong-Won Oh and Choongho Lee and Kyeong Lee",
year = "2014",
month = "3",
day = "21",
doi = "10.1016/j.ejmech.2014.01.062",
language = "English",
volume = "75",
pages = "413--425",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors. / Jin, Guanghai; Lee, Sungjin; Choi, Moonju; Son, Seohyun; Kim, Geon Woo; Oh, Jong-Won; Lee, Choongho; Lee, Kyeong.

In: European Journal of Medicinal Chemistry, Vol. 75, 21.03.2014, p. 413-425.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors

AU - Jin, Guanghai

AU - Lee, Sungjin

AU - Choi, Moonju

AU - Son, Seohyun

AU - Kim, Geon Woo

AU - Oh, Jong-Won

AU - Lee, Choongho

AU - Lee, Kyeong

PY - 2014/3/21

Y1 - 2014/3/21

N2 - In order to identify the inhibitors of hepatitis C virus (HCV) replication with a novel scaffold via a mechanistically unbiased approach, we screened our in-house library composed of ∼6000 compounds with various chemical structures by using the renilla luciferase-linked genotype 2a reporter virus, and we identified a series of compounds containing an indole moiety that were active against HCV replication. Based on this result, we further synthesized three groups of indole derivatives and evaluated their inhibitory effects on HCV replication. In the present structure-activity relationship study of these indole derivatives, we discovered that compound 12e was the most potent inhibitor of HCV replication with minimal cytotoxicity (EC50 = 1.1 μM, EC90 = 2.1 μM, and CC50 = 61.8 μM). We also confirmed that compound 12e caused a dose- and time-dependent reduction of viral RNA as well as viral protein levels in both genotype 2a J6/JFH1 RNA-transfected cells and genotype 1b Bart79I subgenomic replicon cells. Finally, a genetic mapping study of mutant viruses resistant to compound 12e revealed that NS5B RNA polymerase was the potential target. This finding was further validated by demonstration of inhibition of NS5B RNA polymerase in vitro by compound 12e (IC50 = 292 nM). Compound 12e may serve as a valuable candidate for the development of a new class of HCV NS5B RNA polymerase inhibitors in the future.

AB - In order to identify the inhibitors of hepatitis C virus (HCV) replication with a novel scaffold via a mechanistically unbiased approach, we screened our in-house library composed of ∼6000 compounds with various chemical structures by using the renilla luciferase-linked genotype 2a reporter virus, and we identified a series of compounds containing an indole moiety that were active against HCV replication. Based on this result, we further synthesized three groups of indole derivatives and evaluated their inhibitory effects on HCV replication. In the present structure-activity relationship study of these indole derivatives, we discovered that compound 12e was the most potent inhibitor of HCV replication with minimal cytotoxicity (EC50 = 1.1 μM, EC90 = 2.1 μM, and CC50 = 61.8 μM). We also confirmed that compound 12e caused a dose- and time-dependent reduction of viral RNA as well as viral protein levels in both genotype 2a J6/JFH1 RNA-transfected cells and genotype 1b Bart79I subgenomic replicon cells. Finally, a genetic mapping study of mutant viruses resistant to compound 12e revealed that NS5B RNA polymerase was the potential target. This finding was further validated by demonstration of inhibition of NS5B RNA polymerase in vitro by compound 12e (IC50 = 292 nM). Compound 12e may serve as a valuable candidate for the development of a new class of HCV NS5B RNA polymerase inhibitors in the future.

UR - http://www.scopus.com/inward/record.url?scp=84894549522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894549522&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2014.01.062

DO - 10.1016/j.ejmech.2014.01.062

M3 - Article

VL - 75

SP - 413

EP - 425

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -